![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/9/94/Coronavirus._SARS-CoV-2.png/640px-Coronavirus._SARS-CoV-2.png&w=640&q=50)
iNCOVACC
Vaccine candidate against COVID-19 / From Wikipedia, the free encyclopedia
iNCOVACC (codenamed BBV154)[1] is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech,[2][3] American company Precision Virologics[4][5] and the Washington University School of Medicine in St Louis, Missouri, United States.[6][7]
See also: BBV152
Quick Facts Vaccine description, Target ...
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | iNCOVACC |
Routes of administration | Intranasal |
ATC code |
|
Close